Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 3/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.53 |
| ▸ | THRA | P10827 | 11/20 | 0.50 |
| ▸ | THRB | P10828 | 11/20 | 0.50 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.42 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22229868 | 1.00 | EPHX1 (0.53) | EPHX1EPHX2THRATHRBRORC | |
| SCHEMBL22252079 | 0.89 | EPHX1 (0.66) | EPHX1EPHX2THRATHRBRORC | |
| SCHEMBL29674990 | 0.83 | EPHX1 (0.63) | EPHX1EPHX2THRATHRB | |
| SCHEMBL22229870 | 0.83 | EPHX1 (0.63) | EPHX1EPHX2THRATHRB | |
| SCHEMBL22229865 | 0.79 | EPHX1 (0.80) | EPHX1EPHX2THRATHRB | |
| SCHEMBL29675102 | 0.77 | EPHX1 (0.79) | EPHX1EPHX2THRATHRB | |
| SCHEMBL22229866 | 0.77 | EPHX1 (0.79) | EPHX1EPHX2THRATHRB | |
| SCHEMBL22229867 | 0.77 | EPHX1 (0.79) | EPHX1EPHX2THRATHRB | |
| SCHEMBL17930292 | 0.74 | EPHX1 (0.79) | EPHX1EPHX2THRATHRBRORC | |
| SCHEMBL22252089 | 0.73 | EPHX1 (0.80) | EPHX1EPHX2THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220169708-A1 | NANOBODIES AGAINST CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) INHIBITORY FACTOR (Cif) | THE TRUSTEES OF DARTMOUTH COLLEGE | 2022-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169708-A1 | NANOBODIES AGAINST CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) INHIBITORY FACTOR (Cif) | CFTR, CFH, VSIR | EPHX1 4144/4885EPHX2 4216/4885THRA 3008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.